Vitamin D Supplementation Reduces Renin-Angiotensin System Activity in Obesity
NCT ID: NCT01068418
Last Updated: 2017-03-30
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
26 participants
INTERVENTIONAL
2010-02-28
2011-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Specific Aim: To investigate whether Vitamin D supplementation in obesity improves the vascular sensitivity to angiotensin II.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Vitamin D on Renin Expression in Hypertensive Patients
NCT00585442
Vitamin D Effects in Overweight Patients
NCT00493012
The VALIDATE-D Study
NCT01635062
Vitamin D and Blood Pressure
NCT00459563
DAYLIGHT: Vitamin D Therapy in Individuals at High Risk of Hypertension
NCT01240512
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study aims to evaluate whether the supplementation of Vitamin D in obese subjects will lower local tissue RAS activity. RAS activity will be evaluated by cross-sectional measurement of RAS components and by quantifying the vascular response to an infusion of angiotensin II. Subjects will be studied while Vitamin D deficient, and will return for repeat study following Vitamin D supplementation, for comparison.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vitamin D3
15000IU of vitamin D3 daily: open-label, single-arm
Vitamin D (cholecalciferol)
cholecalciferol 15,000 IU daily for 30 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vitamin D (cholecalciferol)
cholecalciferol 15,000 IU daily for 30 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Cr \< 1.6,
* 25-hydroxyvitamin D \< 25 ng/mL,
* BMI \> 30 kg/m2,
* stage I hypertension.
Exclusion Criteria
* coronary heart disease,
* heart failure,
* renal failure,
* liver failure,
* hyperparathyroidism,
* granulomatous disease.
18 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Brigham and Women's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jonathan S. Williams, MD, MMSc
Assistant Professor of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jonathan S Williams, MD, MMSc
Role: PRINCIPAL_INVESTIGATOR
Brigham and Women's Hospital
Anand Vaidya, MD
Role: STUDY_DIRECTOR
Brigham and Women's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Brigham and Women's Hospital
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009p002062
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.